Clinical Trial Update: MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for MAGE-A3 antigen-specific cancer immunotherapeutic in progressive metastatic cutaneous melanoma; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MAGE-A3 antigen-specific cancer immunotherapeutic (MAGE-A3 antigen-specific cancer immunotherapeutic)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2019-06-03